As of June 3, 2025, NanoRepro AG (NN6.DE) reports a Net Margin of 18.27%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of NanoRepro AG's Net Margin
Over recent years, NanoRepro AG's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2021-12-31 | 18.27% |
| 2020-12-31 | 10.01% |
| 2019-12-31 | -97.56% |
| 2018-12-31 | -12.55% |
| 2017-12-31 | -44.24% |
This slight upward trend highlights how NanoRepro AG manages its overall profitability and cost control over time.
Comparing NanoRepro AG's Net Margin to Peers
To better understand NanoRepro AG's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| NanoRepro AG (NN6.DE) | 18.27% |
| Scope Fluidics SA (SCP.WA) | 49939.69% |
| Titan Medical Inc (TMD.TO) | 39.43% |
| Sectra AB (SECT B.ST) | 24.83% |
| Surgical Science Sweden AB (SUS.ST) | 14.89% |
| C Rad AB (CRAD B.ST) | 12.04% |
Compared to its competitors, NanoRepro AG's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.